Modulation of splicing by inhibiting the kinase SRPK1 as a novel therapeutic strategy in myeloid leukemia

被引：0
|
作者：
Tzelepis, Konstantinos
De Braekeleer, Etienne
Seiler, Michael
Barbieri, Isaia
Robson, Sam
Yang, Yu Hsuen
Gozdecka, Malgorzata
Dudek, Monika
Collord, Grace
Dovey, Oliver M.
Metzakopian, Emmanouil
Garyfallos, Dimitrios
Cooper, Jonathan L.
Buonamici, Silvia
Ponstingl, Hannes
Stratton, Michael R.
Bradley, Allan
Huntly, Brian J.
Pina, Cristina
Kouzarides, Tony
Yusa, Kosuke
Vassiliou, George S.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1158
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1158
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SRPK1 inhibition and modulation of VEGF alternative splicing as a potential therapeutic strategy in prostate cancer
    Mavrou, Athina
    Bates, Dave
    Oltean, Sebastian
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Xanthohumol as a potential therapeutic strategy for acute myeloid leukemia: Targeting the FLT3/SRPK1 signaling axis
    Zhang, Duan-Na
    Yang, Wen-Ya
    Hu, Xiao-Xue
    Song, Xiao-Min-Ting
    Guo, Chuan-Jie
    Peng, Fu
    Li, Yu-Zhi
    Cao, Zhi-Xing
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2025, 33 (01)
  • [3] Serine–arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer
    A Mavrou
    K Brakspear
    M Hamdollah-Zadeh
    G Damodaran
    R Babaei-Jadidi
    J Oxley
    D A Gillatt
    M R Ladomery
    S J Harper
    D O Bates
    S Oltean
    Oncogene, 2015, 34 : 4311 - 4319
  • [4] Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer
    Mavrou, A.
    Brakspear, K.
    Hamdollah-Zadeh, M.
    Damodaran, G.
    Babaei-Jadidi, R.
    Oxley, J.
    Gillatt, D. A.
    Ladomery, M. R.
    Harper, S. J.
    Bates, D. O.
    Oltean, S.
    ONCOGENE, 2015, 34 (33) : 4311 - 4319
  • [5] Splicing Kinase SRPK1 Conforms to the Landscape of Its SR Protein Substrate
    Aubol, Brandon E.
    Jamros, Michael A.
    McGlone, Maria L.
    Adams, Joseph A.
    BIOCHEMISTRY, 2013, 52 (43) : 7595 - 7605
  • [6] SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases
    Oltean, Sebastian
    Gammons, Melissa
    Hulse, Richard
    Hamdollah-Zadeh, Maryam
    Mavrou, Athina
    Donaldson, Lucy
    Salmon, Andrew H.
    Harper, Steve J.
    Ladomery, Michael R.
    Bates, David O.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 831 - 835
  • [7] SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
    Mavrou, Athina
    Oltean, Sebastian
    PHARMACOLOGICAL RESEARCH, 2016, 107 : 276 - 281
  • [8] CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1
    Liang, Jing
    Gondane, Aishwarya
    Itkonen, Harri M.
    MOLECULAR ONCOLOGY, 2024, 18 (10) : 2510 - 2523
  • [9] Novel SRPK1 inhibitors specifically target alternative splicing in human primary retinal epithelial cells
    Rowlinson, J.
    Batson, J.
    Toop, H.
    Allen, C.
    Gibbons, B.
    Babaei-Jadidi, R.
    Zhang, J.
    Wearmouth, S.
    Knapp, S.
    Morris, J.
    Bates, D.
    ACTA OPHTHALMOLOGICA, 2015, 93
  • [10] Overexpression of splicing factors SRSF1 and SRSF2 and their regulators, kinase SRPK1 and SRPK2 in bronchial NSCLC carcinomas
    Gout, Stephanie
    Brambilla, Elisabeth
    Gazzeri, Sylvie
    Eymin, Beatrice
    BULLETIN DU CANCER, 2011, 98 : S27 - S27
12345